CJC-1295 With DAC vs. Without DAC: A Researcher's Guide to the Differences

Few pairs of research peptides cause as much confusion as CJC-1295 with DAC and CJC-1295 without DAC. The names are nearly identical, they are often listed side by side in catalogues, and they are frequently mistaken for one another. Yet in the lab they behave very differently, and choosing the wrong one can quietly undermine an experiment.

This guide explains what separates the two, why the difference matters for study design, and how to confirm you actually have the compound you intended to order.

A shared starting point: GHRH(1-29)

Both compounds are built on the first 29 amino acids of growth hormone-releasing hormone (GHRH), the shortest fragment that retains full biological activity at the GHRH receptor. Native GHRH(1-29) is rapidly degraded, so it has limited usefulness as a stable research tool.

To solve this, researchers developed a modified analogue, commonly called Modified GRF (1-29) and also sold as CJC-1295 without DAC or CJC No DAC. It carries four amino acid substitutions (at positions 2, 8, 15, and 27) designed to improve resistance to enzymatic breakdown while preserving receptor activity. Despite the different names, these terms generally describe the same molecule.

What DAC adds

DAC stands for Drug Affinity Complex. In CJC-1295 with DAC, the modified GRF(1-29) sequence is extended with a lysine residue carrying a reactive maleimide group. That group allows the peptide to bind covalently to serum albumin, the most abundant protein in blood plasma.

The effect is a dramatic change in persistence. Albumin acts as a carrier that shields the peptide from clearance, so the half-life stretches from minutes to days. This design principle, attaching a peptide to albumin to extend its lifetime, was described in the original characterisation work by Jetté and colleagues (2005) and has since become a well-known strategy in peptide engineering.

Side-by-side comparison

Feature	CJC-1295 without DAC (Mod GRF 1-29)	CJC-1295 with DAC
Backbone	GHRH(1-29), four substitutions	Same backbone plus lysine-linked maleimide group
Albumin binding	None	Covalent, via DAC
Reported half-life	Roughly 30 minutes	Roughly 6 to 8 days in published studies
Exposure profile	Short, pulse-like	Prolonged, sustained
Typical research use	Studies of acute or episodic receptor activation	Studies of continuous or long-duration receptor stimulation
Molecular weight	Lower	Higher (the DAC group adds measurable mass)

Why the half-life gap matters for experimental design

The central question for any comparison is: what kind of signal are you trying to model?

Pulse-like exposure. Endogenous GHRH is released in bursts. Researchers interested in how cells respond to brief, transient receptor activation, including downstream cAMP signalling and the dynamics of response and recovery, generally find the short-acting variant better suited to the question.

Sustained exposure. Studies examining what happens when the GHRH receptor pathway is stimulated continuously over long periods, including receptor adaptation and desensitisation, point toward the DAC variant, whose persistence is built into its chemistry.

A few practical design considerations follow from this:

• Match the compound to the timescale of your assay. A multi-day readout paired with a compound that is cleared in minutes (or the reverse) can produce results that are difficult to interpret.
• Think about albumin in your system. Because the DAC variant is designed to bind albumin, the albumin content of your medium or buffer may influence how much free compound is available. Serum-containing and serum-free conditions may not be directly comparable, so keep these consistent and document them.
• Use appropriate controls. Include vehicle controls and, where relevant, a comparator from the other variant so that differences in exposure profile can be separated from differences in intrinsic receptor activity.
• Record everything. Batch number, lot-specific purity, storage history, and preparation date all belong in your lab notebook.

Verifying identity: don't assume, confirm

Because the two compounds sound so similar, mix-ups happen. Fortunately, they are analytically distinguishable, which is one more reason batch documentation matters.

• Mass spectrometry (MS) is the clearest check. The DAC variant has a higher molecular weight than the unmodified peptide, so MS data should match the expected mass for the specific compound you ordered.
• HPLC purity tells you what proportion of the sample is the target peptide versus truncated sequences, deletion products, or other synthesis by-products.
• A batch-specific Certificate of Analysis (COA) ties those results to the exact lot you are using, so your findings can be reproduced and audited later.

Before you design an experiment around either compound, take two minutes to confirm that the COA lists the correct identity and mass. SolXgenix publishes COAs in its COA Library so researchers can review analytical data up front.

Handling and storage basics

Like most lyophilised peptides, both variants are generally best kept in a cool, dry, dark environment before use, with repeated freeze-thaw cycles avoided after reconstitution. Always follow the storage guidance accompanying your specific batch, and prepare only what an experiment requires. Consistent handling reduces degradation as a hidden variable.

Key takeaways

• CJC-1295 with DAC and without DAC share the same modified GHRH(1-29) backbone.
• The DAC modification enables albumin binding, extending half-life from roughly 30 minutes to several days.
• The short-acting variant suits pulse-like exposure models; the DAC variant suits sustained-exposure models.
• Albumin content in your experimental system can affect how the DAC variant behaves, so control and report it.
• Confirm identity with mass spectrometry and batch-specific COAs, since the two names are easy to confuse.

Frequently asked questions

What does DAC stand for? Drug Affinity Complex. It refers to a chemical modification that lets the peptide bind covalently to serum albumin, which prolongs its persistence.

Is CJC-1295 without DAC the same as Modified GRF (1-29)? In most research contexts, yes. The terms are used interchangeably for the stabilised GHRH(1-29) analogue that lacks the albumin-binding modification.

Which variant is better for pulsatility research? The shorter-acting, no-DAC variant is generally considered the better fit for models of episodic receptor activation, because its exposure window is brief and defined.

How can I tell the two compounds apart in a lab? Check the molecular weight on the COA or run your own mass spectrometry. The DAC variant is heavier because of the added lysine-linked group.

Where can I find analytical data for SolXgenix peptides? Visit the COA Library at solxgenix.com/coa or browse the research catalogue at solxgenix.com/shop.

Explore: Research Catalog | COA Library | US-Sourced Peptides

Disclaimer: All products on SolXgenix.com are sold strictly for in vitro laboratory research use only. Not for human or veterinary use. Not FDA-approved to diagnose, treat, cure, or prevent any disease. This article is intended for qualified researchers and laboratory professionals and is provided for educational purposes only.